Fixed-Combination Glaucoma Medication Reduces IOP More Than Each Medication Alone | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Wednesday, January 12, 2011

Email

Comments

Ocular Surgery News

Patients with glaucoma or ocular hypertension who received fixed-combination brimonidine-timolol had a better chance of achieving a low mean IOP with less IOP fluctuation than patients who received brimonidine or timolol monotherapy, according to a study.

Glaucoma Testing Equipment / Glaucoma Products »

All of the following drugs are FDA approved for the treatment of minimally classic subfoveal CNV in patients with neovascular AMD with evidence of recent disease progression (loss of vision, growth of CNV on FA, new macular hemorrhage) except for which one?
1. Pegaptanib sodium (Macugen)
2. Verteporfin (Visudyne PDT)
3. Ranibizumab (Lucentis)
4. None of the above
5. All of the above
Check The Answer

SPECTRALIS Diagnostic Imaging Platform
A modular and upgradeable ophthalmic ... view product
OPMI LUMERA 700 Surgical Microscope
OPMI LUMERA 700 Incorporating the latest... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us